Rodent models of amyotrophic lateral sclerosis

Research output: Contribution to journalArticle

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (~40% to 50% of fALS and ~10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.

Original languageEnglish (US)
Pages (from-to)5.67.1-5.67.21
JournalCurrent Protocols in Pharmacology
Volume2015
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Aberrant protein homeostasis
  • Amyotrophic Lateral Sclerosis
  • Glia
  • Motor neuron
  • RNA processing alterations
  • Rodent models

ASJC Scopus subject areas

  • Pharmacology

Cite this